Clinical Trials
24 trialsNCT07609251 2026-05-27
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(Phase II Study Ongoing)
Sinocelltech Ltd.
Phase 2 Not yet recruiting
NCT07590934 2026-05-15
PROSPECTOR
AstraZeneca
Phase 1/2 Not yet recruiting
NCT07524257 2026-05-04
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
ImmunityBio, Inc.
Phase 3 Not yet recruiting
NCT07566052 2026-05-04
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Astellas Pharma Inc
Phase 3 Not yet recruiting
NCT07545044 2026-04-22
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
NCT07518147 2026-04-08
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07518173 2026-04-08
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
NCT07464327 2026-03-11
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Hansoh BioMedical R&D Company
Phase 3 Not yet recruiting
NCT07459751 2026-03-10
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2/3 Not yet recruiting
NCT07442565 2026-03-04
SYNSTAR03
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07416994 2026-02-18
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Not yet recruiting
NCT07361484 2026-01-23
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
BeyondSpring Pharmaceuticals Inc.
Phase 3 Not yet recruiting
NCT06724042 2025-12-10
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Not yet recruiting
NCT07242274 2025-11-21
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
Jemincare
Phase 3 Not yet recruiting
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT07083505 2025-07-24
A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT06925659 2025-04-17
A Study of QLM2011 in Subjects With Advanced Solid Tumors
Qilu Pharmaceutical (Hainan) Co., Ltd.
Phase 1 Not yet recruiting
NCT06892431 2025-03-25
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
NCT06775483 2025-01-15
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical Study
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Not yet recruiting
NCT06525350 2024-07-29
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT06492941 2024-07-09
A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT06394713 2024-05-01
A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06319313 2024-03-20
Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting